Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:17:22 EDT Thu 25 Apr 2024
Enter Symbol
or Name
USA
CA



Z:BMY - BRISTOL-MYERS SQUIBB CO - http://www.bristolmyers.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BMY - Z0.244.74·44.750.144.74-4.12-8.425,339.51,138,71899,58947.50  47.50  44.6170.935  47.5812:58:0306:5915 min RT 2¢

Recent Trades - Last 10 of 99589
Time ETExPriceChangeVolume
12:58:13Z44.725-4.1355
12:58:13Z44.72-4.14125
12:58:12Z44.725-4.135200
12:58:11Z44.725-4.1351
12:58:11Z44.725-4.135100
12:58:11Z44.725-4.135200
12:58:11Z44.725-4.135200
12:58:11Z44.725-4.135100
12:58:10Z44.725-4.1351
12:58:10Z44.7216-4.138497

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-25 06:59U:BMYNews ReleaseBristol Myers Squibb Reports First Quarter Financial Results for 2024
2024-04-22 06:59U:BMYNews ReleaseBristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
2024-04-11 09:11U:BMYNews ReleaseBuilding a Better Future: Bristol Myers Squibb 2023 ESG Report
2024-04-08 11:30U:BMYNews ReleaseKRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
2024-04-08 07:03U:BMYNews ReleaseBristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals
2024-04-06 13:15U:BMYNews ReleaseBristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
2024-04-06 13:15U:BMYNews ReleaseBristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
2024-04-05 09:05U:BMYNews ReleaseU.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
2024-04-02 20:08U:BMYNews ReleaseEuropean Commission Expands Approval of Bristol Myers Squibb's Reblozyl(TM) (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
2024-04-02 14:32U:BMYNews ReleaseBristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
2024-03-29 09:46U:BMYNews ReleaseBristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
2024-03-28 16:05U:BMYNews ReleaseBristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
2024-03-28 16:01U:BMYNews ReleaseBristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease